Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II/III Trial of SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma

NCT03552549 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT03552549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03552549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II/III Trial of SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron) vs. INTRON®A as Adjuvant Therapy for Melanoma
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2/3
Overall status
Terminated
Start date
August 5, 1998
Completion date
February 19, 2001
Enrollment
126 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma